Companies: 10,795·Total market cap: $144.5T
AstraZeneca PLC

AstraZeneca PLC

AZNNYSEHealthcare● Active
$185.95
+$4.15(+2.28%)
Market Cap$288.4B
P/E Ratio—
52W High$212.71
52W Low$137.22
Cash on HandFinancialsRevenue

AstraZeneca PLC (AZN) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

AZN · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$5.74B▲ +3.9% vs prior year
FY · as of Dec 31, 2025 · Reported in USD
Cash & Cash Equiv. (CCE)
$5.71B
cashAndCashEquivalents
Short-Term Investments
$30.0M
shortTermInvestments
YoY Change vs Prior Year
+3.9%
vs prior fiscal year
Latest Quarter
$7.67B
Q1 2026
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$5.74BCash on Hand
Total Debt$29.70BTotal Debt
Net Cash / Net Debt−$23.96BNet Debt Position
Cash vs Debt Ratio
Cash 16%Debt 84%

AstraZeneca PLC carries a net debt position of $23.96B. Total debt ($29.70B) exceeds cash on hand ($5.74B). AstraZeneca PLC cash vs debt ratio: 16% cash / 84% debt.

Net Cash = Cash & ST Investments − Total Debt$5.74B − $29.70B = −$23.96B

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
AZN annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$5.74B+3.9%
Dec 31, 2024$5.53B-5.7%
Dec 31, 2023$5.86B-6.1%
Dec 31, 2022$6.24B-2.4%
Dec 31, 2021$6.40B-19.9%
AZN cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.8%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%
#4
AstraZeneca PLC
AstraZeneca PLCYOU
AZN
$5.74B2.0%
#5
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

AstraZeneca PLC (AZN) cash on hand as of December 31, 2025 is $5.74B, comprising $5.71B in cash and cash equivalents (CCE) plus $30.0M in short-term investments — reported as AstraZeneca PLC cash and short-term investments on the balance sheet (10-K filing). Also referred to as AstraZeneca PLC cash reserves or cash position.

AstraZeneca PLC annual cash on hand history shows increased +3.9% in 2025: increased +3.9% in 2025. AstraZeneca PLC cash reserves in 2025 reflect the company's capital allocation strategy.

AstraZeneca PLC carries total debt of $29.70B against cash of $5.74B, resulting in a net debt position of -$23.96B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

AZN cash on hand · 5 questions

As of December 31, 2025, AstraZeneca PLC (AZN) has $5.74B in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $5.71B in cash and cash equivalents (CCE) plus $30,000,000 in short-term investments. Latest quarter (March 31, 2026): $7.67B. Data sourced from the annual 10-K filing via FMP.

AZN cash on handAZN cash reservesAZN cash 2025how much cash does AZN have

▸ Source: FMP /balance-sheet-statement · US GAAP · AstraZeneca PLC · AstraZeneca PLC SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025